Figure 2. (a-c) Molecular docking of promethazine and levomepromazine.

a. Docking of promethazine (in purple) and levomepromazine (in blue) into the binding site of human TCTP (PDB code: 2HR9 in surface representation, blue surface represents Ca²⁺ binding site, TCTP residues: 1-70 [32]; pink surface represents p53 binding site, TCTP residues: 70-119 [52] and grey surface represents Bcl-xL binding site, TCTP residues: 20-27 [51]). Levomepromazine (blue) occupied the same binding site as promethazine (purple). Docked structure of promethazine b. and levomepromazine c. in the human TCTP binding pocket. d-f. Molecular docking of hydroxyzine and buclizine. (d) Docking of hydroxyzine (in red) and buclizine (in orange) into the binding site of human TCTP (PDB code: 2HR9 in blue surface representation (Ca²⁺ binding site)). Buclizine (orange) occupied the same binding site as hydroxyzine (red). Docked structure of hydroxyzine (e) and buclizine (f) in the human TCTP binding pocket. The residues involved in hydrogen bond interaction are labeled and hydrogen bonds are shown as green dots.